Minutes: Steering Board meeting, 8 and 11 January 2021

1. Update from AstraZeneca on the state of play and the latest developments (separate report)

2. Top-up on BioNTech/Pfizer

Following the exploratory discussions that the Commission was mandated to carry with BioNTech/Pfizer in order to reach an agreement for a larger top-up volume in conjunction with an [REDACTED], the Commission proposed to the EU Member States to:

- purchase [REDACTED],
- with the option to acquire [REDACTED].

The Commission indicated that, based on this volume, the top-up doses would be delivered [REDACTED] 2021.

More precisely, the indicative delivery would be the following [REDACTED]:

- [REDACTED] 2021
- [REDACTED] 2021
- [REDACTED] 2021

This would, therefore, enable the EU to purchase [REDACTED] million doses of this vaccine which is already being used across the EU, thus meeting the needs expressed by the Member States. This agreement could provide a solution to the [REDACTED] Member States [REDACTED] as they would get the quantities needed and also the [REDACTED].

This would also allow to take into account the external dimension and help for resale and donation activities.

The Commission stressed that this offer would need to be endorsed by the Member States, and therefore called the Members to indicate the top-up volume they are interested in, within the [REDACTED] (MSs do not need to express any interest for the [REDACTED]).

If MSs would not be able to agree with the number of doses proposed, the offer would need to be revisited [REDACTED].

The Member States welcomed this news. They welcomed also the fact that [REDACTED].
It was clarified that, should the Member States agree to this top-up:

- This was welcomed by the Member States.
- procedurally, the instrument would require a College decision. The MSs would benefit of the five-day opt-out period that applied to the original contact.

A discussion was held on FMA’s CHMP recommendation which clarified that each vial of BioNTech/Pfizer vaccines contained six doses of the vaccine.

The Members discussed the implications of the recommendation on the delivery of the doses (number of vials).

An important number of MSs expressed the wish to keep the number of vials.

3. Update on the

Moderna- the company was missing documents from some MSs, necessary for the first shipments. This was clarified later during a dedicated meeting with Moderna representatives.

Curevac- the Members were reminded that the deadline for feedback on the allocation table lapsed.

4. Meeting with Moderna

The Moderna representatives updated the Members of the Steering Board on the deliveries. For some Member States there seemed to be issues regarding the local preparedness (eg. qualified freezers). However, no major issue was identified.

The Company also stressed that a number of MSs still needed to send the company some missing documents, namely:
1. Update on AstraZeneca

The Members were informed about the outcome of the Commission’s discussion where AZ was requested to give an update on the regulatory process ongoing and on the steps the company was taking to address requests by the rapporteurs.

Regarding the conditions mentioned, Members were informed that AZ was working on the progress report based on the request from the Commission in the letter transmitted and would present the report in the coming days.

The Members were informed that AZ was requested to submit a delivery schedule, as follows:

AZ raised the issue of the optional doses foreseen in the contract. Commission informed that the issue has been raised with MS but feedback was still outstanding.

2. Update on ongoing negotiations and on discussions with other companies

- Novavax - following the agreement of the Steering Board, and the negotiations on the detailed contract would begin in the coming days. The Steering Board decided on

- Valneva - Members were updated on discussions regarding the key elements: delivery schedule, price, vaccine characteristics etc. The Steering Board decided on

3. Update on the

4. Curevac

The Members were reminded that the deadline for feedback on the allocation table lapsed. The process was on hold until agreed to a reshuffle of doses. These MSs were encouraged to find an agreement as the deadline had expired
BioNTech /Pfizer- Optional/Additional doses - some Member States still needed to provide with an updated Order Form.

BioNTech /Pfizer- Top up

The Members were requested to indicate if they would opt out of the contract.

It was concluded that the overwhelming majority of the Member States was positive to the top-up as proposed. Only [redacted] Member States expressed reservations. Staying in the amended contract would allow all MSs to benefit from the contractual clauses and would prevent later issues.

and the Steering board concluded that there was sufficient interest/support for top-up doses.

The Steering Board discussed again the EMA’s CHMP recommendation clarifying that each vial of BioNTech/Pfizer vaccines contained six doses of the vaccine. A large number of MSs expressed the wish to keep the number of vials [redacted]

Moderna - Top up

The Members were requested to indicate as soon as possible whether they wanted or not top-up doses for Modera vaccine, as clarity was necessary on then overall